OBJECTIVE: Besides interleukin (IL)-10, accumulating evidence from in vitro studies has indicated a strong antiinflammatory capacity for IL-13. A prospective clinical study was undertaken to assess the influence of additional brain injury on systemic IL-10 and IL-13 levels as markers for the antiinflammatory state in trauma patients. MATERIAL AND METHODS: The course of IL-10 and IL-13 plasma levels from 32 patients with an isolated severe head trauma (SHT), 50 patients with multiple injuries and additional SHT and 39 patients with multiple injuries without SHT was detected using ELISA-technique. Blood samples from 37 healthy blood donors were analysed for control. RESULTS: IL-10 levels were significantly elevated in all 3 injury groups within 3 h after trauma. The lowest initial release was detected in patients with an isolated SHT (Injury severity score; ISS: 18.1 +/- 5.6). No difference could be demonstrated for the IL-10 levels from multiple injured patients with (ISS: 35.3 +/- 9.6) or without additional SHT (ISS: 25.5 +/- 11.7), though there were relevant differences in the ISS. In contrast, the IL-13 plasma levels were not elevated systemically after trauma. CONCLUSIONS: IL-10 but not IL-13 is a detectable antiinflammatory marker in trauma patients with or without brain injury and to a minor degree in patients with an isolated SHT.
OBJECTIVE: Besides interleukin (IL)-10, accumulating evidence from in vitro studies has indicated a strong antiinflammatory capacity for IL-13. A prospective clinical study was undertaken to assess the influence of additional brain injury on systemic IL-10 and IL-13 levels as markers for the antiinflammatory state in traumapatients. MATERIAL AND METHODS: The course of IL-10 and IL-13 plasma levels from 32 patients with an isolated severe head trauma (SHT), 50 patients with multiple injuries and additional SHT and 39 patients with multiple injuries without SHT was detected using ELISA-technique. Blood samples from 37 healthy blood donors were analysed for control. RESULTS:IL-10 levels were significantly elevated in all 3 injury groups within 3 h after trauma. The lowest initial release was detected in patients with an isolated SHT (Injury severity score; ISS: 18.1 +/- 5.6). No difference could be demonstrated for the IL-10 levels from multiple injured patients with (ISS: 35.3 +/- 9.6) or without additional SHT (ISS: 25.5 +/- 11.7), though there were relevant differences in the ISS. In contrast, the IL-13 plasma levels were not elevated systemically after trauma. CONCLUSIONS:IL-10 but not IL-13 is a detectable antiinflammatory marker in traumapatients with or without brain injury and to a minor degree in patients with an isolated SHT.
Authors: E Acar; A Demir; Ö D Alatas; H Beydilli; B Yıldırım; U Kırlı; D B Hazer; M R Kılınç; Ü Karagöz; S Derin Journal: Eur J Trauma Emerg Surg Date: 2015-10-19 Impact factor: 3.693
Authors: Todd A Baker; Jacqueline Romero; Harold H Bach; Joel A Strom; Richard L Gamelli; Matthias Majetschak Journal: Crit Care Med Date: 2012-03 Impact factor: 7.598
Authors: Joshua M Garcia; Stephanie A Stillings; Jenna L Leclerc; Harrison Phillips; Nancy J Edwards; Steven A Robicsek; Brian L Hoh; Spiros Blackburn; Sylvain Doré Journal: Front Neurol Date: 2017-06-12 Impact factor: 4.003
Authors: Alex P Di Battista; Shawn G Rhind; Michael G Hutchison; Syed Hassan; Maria Y Shiu; Kenji Inaba; Jane Topolovec-Vranic; Antonio Capone Neto; Sandro B Rizoli; Andrew J Baker Journal: J Neuroinflammation Date: 2016-02-16 Impact factor: 8.322